XOMA Corporation (XOMA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
XOMA Corporation (XOMA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document.

*We look forward to being of service to you.*

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

**Phone:** +44 (0)7887 945155 or **Email:** pdb@biportfolio.co.uk
XOMA Corporation (XOMA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Xoma Corporation (Xoma), formerly Xoma Ltd., is a biopharmaceutical company that discovers, develops antibody-based therapeutics. Its lead product, gevokizumab, is a monoclonal antibody used for the treatment of a wide variety of inflammatory diseases and other diseases. Its other pipeline products include XMet, XOMA 3AB, HCD122, FDC1 and LFA102. XMet is used for the potential treatment of diabetes and other metabolic syndromes; XOMA 3AB is used to neutralize the botulinum toxin; HCD122 and LFA102 are in development for the treatment of prostate or breast cancer; FDC1 is used for the treatment of hypertension. Xoma has developed its proprietary antibody discovery, optimization and development technologies, comprising ADAPT, ModulX and OptimX. It operates through its subsidiaries in Bermuda, Ireland, and the US. Xoma is headquartered in Berkeley, California, the US.

XOMA Corporation (XOMA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.

- Business Description - A brief description of the company’s operations.

- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors - A list of the key competitors of the company.

- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

 Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Additional Details

Publisher : Global Data
Reference : GDPH81739D
Number of Pages : 48
Report Format : PDF
Publisher Information : 

https://www.bioportfolio.co.uk/product/12196 pdb@bioportfolio.co.uk to order
Table Of Contents for XOMA Corporation (XOMA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Published by Global Data]

- Table of Contents
- List of Tables
- List of Figures
- 4XOMA Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
- 5XOMA Corporation, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016
- 6XOMA Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016
- 7XOMA Corporation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016
- 8XOMA Corporation, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016
- 9XOMA Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016
- 10XOMA Corporation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016
- 11XOMA Acquires US Rights To Perindopril Franchise From Les Laboratoires Servier
- 12Partnerships
- 13Oncobiologics Enters Into Agreement With Xoma To Develop Novel Botherapeutics
- 14Novo Nordisk Enters into Licensing Agreement with XOMA
- 15Novartis Enters into Licensing Agreement with XOMA
- 16XOMA to Terminate Licensing Agreement with Les Laboratoires Servier for XOMA 052
- 17Xoma Enters into Licensing Agreement with Texas A&M University System
- 18Symplmed Pharma Enters Into Licensing Agreement With Xoma For Perindopril Franchise
- 19XOMA Enters into Licensing Agreement with Margaux Biologics for BPI
- 2021Xoma Plans To Enter Into Licensing Agreement For Perindopril
- 2122Equity Offering
- 2223Xoma Prices Private Placement of Shares and Warrants for USD40 Million
- 2324Xoma Completes Public Offering Of Shares For US$57.4 Million
- 2526Xoma Completes Public Offering Of Shares For US$31.6 Million
- 2728Xoma Completes Public Offering Of Shares For US$40 Million
- 2930XOMA Completes Public Offering Of Common Stock For US$39 Million
- 3132XOMA Completes Public Offering Of Common Stock For US$6.7 Million
- 3334XOMA Completes Public Offering Of US$30 Million
- 3536Xoma Completes First Tranche Of Private Placement Of US$14.2 Million
- 3738XOMA Completes Underwritten Public Offering Of US$21 Million
- 3940Asset Transactions
- 4142Agenus Acquires Antibody Manufacturing Facilities from XOMA
- 4344CMC Biologics Assumes Manufacturing Operations And Affiliated Assets From Xoma
- 4445XOMA Sells Royalty Rights Of Cimzia
- 454644XOMA Corporation - Key Competitors
- 4647Key Employees
- 4748Locations And Subsidiaries
- 4849Head Office
- 4950Other Locations & Subsidiaries
- 5051Appendix
- 5152Methodology
- 5253About GlobalData
- 5354Contact Us
- 5455Disclaimer
## List Of Tables in XOMA Corporation (XOMA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Published by Global Data]

### List of Tables

<table>
<thead>
<tr>
<th>Table Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>XOMA Corporation, Pharmaceuticals &amp; Healthcare, Key Facts, 2014</td>
<td>1</td>
</tr>
<tr>
<td>XOMA Corporation, Pharmaceuticals &amp; Healthcare, Deals By Year, 2010 to YTD 2016</td>
<td>5</td>
</tr>
<tr>
<td>XOMA Corporation, Pharmaceuticals &amp; Healthcare, Deals By Type, 2010 to YTD 2016</td>
<td>6</td>
</tr>
<tr>
<td>XOMA Corporation, Pharmaceuticals &amp; Healthcare, Deals By Region, 2010 to YTD 2016</td>
<td>7</td>
</tr>
<tr>
<td>XOMA Corporation, Deals By Therapy Area, 2010 to YTD 2016</td>
<td>8</td>
</tr>
<tr>
<td>XOMA Corporation, Pharmaceuticals &amp; Healthcare, Deals Summary, 2010 to YTD 2016</td>
<td>9</td>
</tr>
<tr>
<td>XOMA Acquires US Rights To Perindopril Franchise From Les Laboratoires Servier</td>
<td>11</td>
</tr>
<tr>
<td>Oncobiologics Enters Into Agreement With Xoma To Develop Novel Botherapeutics</td>
<td>12</td>
</tr>
<tr>
<td>Novo Nordisk Enters into Licensing Agreement with XOMA</td>
<td>13</td>
</tr>
<tr>
<td>Novartis Enters into Licensing Agreement with XOMA</td>
<td>15</td>
</tr>
<tr>
<td>XOMA to Terminate Licensing Agreement with Les Laboratoires Servier for XOMA 052</td>
<td>16</td>
</tr>
<tr>
<td>Xoma Enters into Licensing Agreement with Texas A&amp;M University System</td>
<td>18</td>
</tr>
<tr>
<td>Symplmed Pharma Enters Into Licensing Agreement With Xoma For Perindopril Franchise</td>
<td>19</td>
</tr>
<tr>
<td>XOMA Enters into Licensing Agreement with Margaux Biologics for BPI</td>
<td>21</td>
</tr>
<tr>
<td>Xoma Plans To Enter Into Licensing Agreement For Perindopril</td>
<td>22</td>
</tr>
<tr>
<td>Xoma Prices Private Placement of Shares and Warrants for USD40 Million</td>
<td>23</td>
</tr>
<tr>
<td>Xoma Completes Public Offering Of Shares For US$57.4 Million</td>
<td>25</td>
</tr>
<tr>
<td>Xoma Completes Public Offering Of Shares For US$31.6 Million</td>
<td>27</td>
</tr>
<tr>
<td>Xoma Completes Public Offering Of Shares For US$40 Million</td>
<td>29</td>
</tr>
<tr>
<td>XOMA Completes Public Offering Of Common Stock For US$39 Million</td>
<td>31</td>
</tr>
<tr>
<td>XOMA Completes Public Offering Of Common Stock For US$6.7 Million</td>
<td>33</td>
</tr>
<tr>
<td>XOMA Completes Public Offering Of US$30 Million</td>
<td>35</td>
</tr>
<tr>
<td>Xoma Completes First Tranche Of Private Placement Of US$14.2 Million With Azimuth Opportunity</td>
<td>37</td>
</tr>
<tr>
<td>XOMA Completes Underwritten Public Offering Of US$21 Million</td>
<td>39</td>
</tr>
<tr>
<td>Agenus Acquires Antibody Manufacturing Facilities from XOMA</td>
<td>41</td>
</tr>
<tr>
<td>CMC Biologics Acquires Manufacturing Operations And Affiliated Assets From Xoma</td>
<td>43</td>
</tr>
</tbody>
</table>
List Of Figures, Charts and Diagrams in XOMA Corporation (XOMA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Published by Global Data]

List of Figures

XOMA Corporation, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
XOMA Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
XOMA Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
XOMA Corporation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
XOMA Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
XOMA Corporation, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
XOMA Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
XOMA Corporation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
How to Buy...

XOMA Corporation (XOMA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
[Published by Global Data]

Option 1 - Online
Go to our website and pay online with any major debit or credit card:

https://www.bioportfolio.co.uk/product/12196

Option 2 - Request a Proforma Invoice
Fill in the details below, and either Scan this page and email it to us at pdb@bioportfolio.co.uk
or Fax it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

- Your Name:
- Job Title:
- Your Email:
- Your Contact Phone:
- Company Name:
- Address:
- Post/Zip Code:
- Country:
- P.O. Number:
- Any Other Instructions:

Pricing Options: (please tick one)
- $250 | Single User Price
- $500 | Site License Price
- $750 | Enterprise License Price

Payment Options: (please tick one)
- Online Credit Card (we will email you the invoice with a payment link)
- Direct Wire Transfer (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155
We will be delighted to give you our personal attention.